Business Context and Reporting Period
This Form 8-K Current Report was filed by Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) on March 11, 2025. The report details significant changes to the Company's Board of Directors, including the resignation of two directors and the appointment of two new directors effective March 11, 2025.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
Resignations
- Natasha Giordano: Resigned from the Board, Audit Committee, and Nominating and Corporate Governance Committee effective February 11, 2025, due to other professional obligations. The resignation was not the result of a material disagreement.
- Matthew Wikler: Resigned from the Board and Compensation Committee effective February 11, 2025, due to other professional obligations. The resignation was not the result of a material disagreement.
Appointments
- Keith Murphy: Appointed as a director effective March 11, 2025. He will serve on the Compensation Committee and as Chair of the Governance Committee. He is currently Executive Chairman of Organovo Holdings, Inc. and CEO/Chairman of Viscient Bio.
- Edward Neugeboren: Appointed as a director effective March 11, 2025. He will serve on the Audit Committee and as Chair of the Compensation Committee. He is currently Chief Strategy Officer of Cronus Pharma, LLC and qualifies as an "audit committee financial expert."
Both new directors are deemed independent under NYSE rules and will be compensated under the Company's standard non-employee director compensation plan.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on business outlook, or new risk factors. The Company confirmed there are no reportable related party transactions with the new directors.
Key Facts for Investor Verification
- Verify the independence status and specific committee assignments of new directors Keith Murphy and Edward Neugeboren.
- Confirm that the resignations of Natasha Giordano and Matthew Wikler were not related to any undisclosed disagreements regarding the Company's operations or financial reporting.
- Review the Company's standard non-employee director compensation plan to understand the financial impact of the new appointments.
- Check for subsequent filings (e.g., 10-Q or 10-K) for the most recent financial performance data, as this 8-K contains no financial metrics.